Concepedia

Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab

Jeeyun Lee, Yong Sang Hong, Jung Yong Hong, Se Won Han, Tae Won Kim, Hye Jin Kang, Tae You Kim, Kyu-pyo Kim, Suk Hyung Kim, In‐Gu Do,

Investigational New Drugs · 2014 · 38 citations · 12 references

DOI

Concepts

References

12

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre et al. · New England Journal of Medicine · 2009 · 3.9K citations · Full text

, , +17

<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

Christos S. Karapetis, Shirin Khambata‐Ford, Derek J. Jonker et al. · New England Journal of Medicine · 2008 · 3.6K citations

, , +17

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Axel Grothey, Eric Van Cutsem, Alberto Sobrero et al. · The Lancet · 2012 · 2.9K citations

, , +10

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

, , +13

Direct multiplexed measurement of gene expression with color-coded probe pairs

Gary Geiss, Roger E. Bumgarner, Brian Birditt et al. · Nature Biotechnology · 2008 · 2.1K citations

, , +15